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Abstract
Background: The clinicopathological characteristics and outcomes of mucinous gastric adenocarcinoma (GC)
remain unclear. We report the clinicopathological features and prognosis of patients with mucinous histology who
underwent radical-intent gastrectomy.
Methods: We reviewed the medical records of 1470 patients with pathologically proven undifferentiated GC undergoing
radical-intent gastrectomy between 1995 and 2007. The patients were stratified into three groups according to their
histological type: mucinous carcinoma (MC), signet ring cell carcinoma (SRCC), and poorly differentiated carcinoma (PDC).
Clinicopathological factors affecting prognosis were collected prospectively and analyzed.
Results: In stage III MC, the age and size were significantly greater and larger than in SRCC and PDC; a lower proportion
of perineural invasion was identified in MC, and female predominance was noted in SRCC in comparison with MC and
PDC. The cumulative overall survival rates of stage I–III GC patients with MC were significantly superior compared
to those with PDC, but not SRCC. Stage III GC patients with MC had a better prognosis than those with SRCC or
PDC; the difference in survival was not evident in stages I or II.
Conclusions: Thus, MC presents with different clinicopathological features and prognosis from SRCC and PDC.
The patients with stage III gastric MC had favorable outcomes.
Keywords: Mucinous gastric cancer, Undifferentiated, Prognostic factor
Background
Despite the decreasing overall worldwide incidence of
gastric adenocarcinoma (GC), GC has remained the
third leading cause of cancer-related death, after lung
and liver malignancies, leading to around 723,000 deaths
in 2012 [1]. Most GC patients present with locally ad-
vanced or metastatic disease, and radical surgical re-
section is still the mainstay of treatment for localized
disease [2, 3]. According to the Japanese classification
for histological typing for GC, mucinous carcinoma
(MC) or signet ring cell carcinoma (SRCC) is defined
as the undifferentiated type [4]. Undifferentiated
carcinoma also has different biological behaviors than
differentiated carcinoma, such as the growth pattern,
invasiveness, metastasis, and prognosis [5]. However,
even between tumors belonging to the undifferentiated
histology subtype, there can be significant heterogeneity in
terms of tumor biology and prognosis. Studies reported
that MC accounts for 2.6–7.6 % of all GC [6]. Only a few
studies on gastric MC have been reported, and its clini-
copathological features and prognosis were inconsistent
[5–7]. For example, Yin et al. indicated that there was
no difference in survival between MC and non-MC [6].
However, Kunisaki et al. observed that MC had a poor
prognosis compared with non-MC [7]. The aims of this
* Correspondence: hsujt2813@adm.cgmh.org.tw
1Department of General Surgery, Chang Gung Memorial Hospital at Linkou,
Chang Gung University College of Medicine, 5, Fushing Street, Kweishan
District, Taoyuan City 333, Taiwan
Full list of author information is available at the end of the article
© 2016 Hsu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hsu et al. World Journal of Surgical Oncology  (2016) 14:123 
DOI 10.1186/s12957-016-0886-5
Table 1 Clinicopathological characteristics of stage I–III undifferentiated gastric adenocarcinoma in terms of histology type
Parameters MC (n = 54) SRCC (n = 545) PDC (n = 871) P value
Age (years), mean ± SD 64.2 ± 10.7 58.4 ± 13.4 62.5 ± 13.8 <0.0001
Median 66.0 59.0 65.0
Sex <0.001
Male 31 (57.4) 269 (49.4) 522 (59.9)
Female 23 (42.6) 276 (50.6) 349 (40.1)
Tumor size (cm), mean ± SD 6.4 ± 3.9 4.3 ± 3.4 5.1 ± 3.2 <0.0001
Median 5.5 3.5 4.5
Type of gastrectomy 0.006
Total 16 (29.6) 133 (24.4) 282 (32.4)
Subtotal 38 (70.4) 412 (75.6) 589 (67.6)
Extent of LN dissection 0.773
<D2 21 (38.9) 187 (34.3) 308 (35.4)
≥D2 33 (61.1) 358 (65.7) 563 (64.6)
No. of LN retrieval, mean ± SD 27.3 ± 15.8 28.1 ± 15.3 27.7 ± 14.7 0.856
Median 23.0 25.0 25.0
T status <0.0001
T1 2 (3.7) 163 (29.9) 101 (11.6)
T2 9 (16.7) 56 (10.3) 74 (8.5)
T3 3 (5.6) 19 (3.5) 24 (2.8)
T4 40 (74.1) 307 (56.3) 672 (77.2)
LN status
N0 13 (24.1) 251 (46.1) 244 (28.0) <0.0001
N1 11 (20.4) 59 (10.8) 119 (13.7)
N2 12 (22.2) 66 (12.1) 56 (17.9)
N3 18 (33.3) 169 (31.0) 352 (40.4)
Stage <0.0001
I 5 (9.3) 190 (34.9) 120 (13.8)
II 10 (18.5) 94 (17.2) 170 (19.5)
III 39 (72.2) 261 (47.9) 581 (66.7)
Positive margins (R1 resection) 8 (14.8) 59 (10.8) 95 (10.9) 0.662
Lymphatic invasiona <0.0001
No 21 (39.6) 288 (53.4) 315 (36.7)
Yes 32 (60.4) 251 (46.6) 544 (63.3)
Vascular invasiona 0.005
No 44 (83.0) 479 (89.2) 710 (82.9)
Yes 9 (17.0) 58 (10.8) 146 (17.1)
Perineural invasiona 0.001
No 27 (51.9) 294 (54.9) 380 (44.3)
Yes 25 (48.1) 242 (45.1) 477 (55.7)
Complicationsb 12 (22.2) 61 (11.2) 136 (15.6) 0.016
Surgery-related 10 (18.5) 49 (9.0) 99 (11.4) 0.064
Leakage 5 (9.3) 26 (4.8) 46 (5.3)
Intra-abdominal abscess 4 (7.4) 18 (3.3) 38 (4.4)
Wound infection 1 (1.9) 5 (0.9) 22 (2.5)
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study were to elucidate the clinicopathological characteris-
tics and to clarify the prognosis of stage I–III resected GC




The study protocol was approved by the Institutional
Review Board of Chang Gung Memorial Hospital (No.
100-4279B). Written informed consent was obtained
from all the patients. All data were stored in the hospital
database and used for research.
Patients and surgical procedures
We reviewed the medical records of 1470 patients with
pathologically proven undifferentiated GC undergoing
radical-intent gastrectomy at Chang Gung Memorial
Hospital, Taoyuan, Taiwan, between 1995 and 2007; pa-
tients with a history of partial gastrectomies were ex-
cluded. The patients were stratified into three groups
according to the histological types: MC, SRCC, and
poorly differentiated carcinoma (PDC). Subtotal or total
gastrectomy was performed according to the tumor
size, location of tumor, and status of resection margins.
The standard procedure included a spleen- and pancreas-
preserving D1 or D2 lymph node dissection, depending
on the perceived extent of tumor invasion and lymph
node metastasis [2]. Resection of adjacent organs was
undertaken to achieve clear margins when deemed
necessary [8]. Surgery-related complications included
anastomotic/duodenal stump leakage, wound infec-
tion, intra-abdominal abscess/bleeding, and delayed
gastric emptying, while pneumonia, cardiovascular event,
atelectasis, sepsis, paralytic ileus, pleural effusion, urinary
retention, and psychoneurologic event were considered as
surgery-unrelated complications. Lymphatic, vascular, or
perineural invasion was defined as the presence of per-
meation of the tumor in the lymphatic duct, vascular
structure, or nerve microscopically, respectively. The
tumors were staged according to the seventh edition of
the American Joint Committee on Cancer Tumor Node
Metastasis classification [9]. Postoperative adjuvant
chemotherapy with fluoropyrimidine-based or platinum-
based regimens was indicated for patients with stage II–III
disease, while patients with stage IB did not routinely
received adjuvant chemotherapy except for those with
tumors showing poor differentiation or lymphatic, vas-
cular, or perineural invasion. No patient received neo-
adjuvant chemotherapy. The median follow-up time
was 41.0 months, ranging from 1.2 to 215.9 months.
The patients who died after surgery during the same
hospitalization were defined as hospital mortality and
were not included in the long-term survival analysis.
Survival duration was calculated from the time of surgery
to death or the last follow-up date (December 31, 2012),
irrespective of the cause of death.
Statistical analysis
Clinical records were compared with either Fischer’s
exact test or Pearson’s χ2 test, as appropriate. The patient
survival rate was calculated using the Kaplan-Meier curve,
and univariate analysis was conducted using the log-rank
test. Factors that were deemed of potential importance to
the univariate analysis (P < 0.05) were included in the
multivariate analysis using the Cox regression model.
P < 0.05 was considered significant. Statistical analyses
Table 1 Clinicopathological characteristics of stage I–III undifferentiated gastric adenocarcinoma in terms of histology type
(Continued)
Bleeding 1 (1.9) 9 (1.7) 11 (1.3)
Delayed gastric emptying 0 1(0.2) 6 (0.7)
Others 1 (1.9) 3 (0.6) 4 (0.5)
Surgery unrelated 3 (5.6) 19 (3.5) 59 (6.8) 0.031
Pneumonia 1 (1.9) 2 (0.4) 15 (1.7)
Cardiovascular event 1 (1.9) 5 (0.9) 7 (0.8)
Sepsis 0 2 (0.4) 8 (0.9)
Paralytic ileus 0 2 (0.4) 5 (0.6)
Atelectasis 0 0 6 (0.7)
Others 4 (7.4) 21 (3.9) 45 (5.2)
Hospital mortality 4 (7.4) 14 (2.6) 33 (3.8) 0.130
Chemotherapyc 38 (84.4) 285 (81.7) 553 (75.6) 0.047
Figures are numbers with percentages in parentheses, unless otherwise stated
LN lymph node, MC mucinous carcinoma, PDC poorly differentiated carcinoma, SD standard deviation, SRCC signet ring cell carcinoma
aSome data were missing
bNumber of patients with event
cExcluding T1/T2N0 cases or hospital mortality
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Table 2 Clinicopathological characteristics of stage III undifferentiated gastric adenocarcinoma in terms of histology type
Parameters MC (n = 39) SRCC (n = 261) PDC (n = 581) P value
Age (years), mean ± SD 64.5 ± 10.0 60.2 ± 13.7 62.7 ± 14.0 0.019
Median 66.0 61.0 66.0
Sex 0.002
Male 22 (56.4) 128 (49.0) 359 (61.8)
Female 17 (43.6) 133 (51.0) 222 (38.2)
Tumor size (cm), mean ± SD 7.6 ± 3.9 6.0 ± 3.7 5.8 ± 3.1 0.006
Median 7.0 5.0 5.0
Type of gastrectomy 0.696
Total 13 (33.3) 96 (36.8) 226 (38.9)
Subtotal 26 (66.7) 165 (63.2) 355 (61.1)
Extent of LN dissection 0.268
<D2 13 (33.3) 71 (27.2) 190 (32.7)
≥D2 26 (66.7) 190 (72.8) 391 (67.3)
No. of LN retrieval, mean ± SD 29.2 ± 16.3 30.2 ± 16.2 28.6 ± 14.9 0.373
Median 25.0 27.0 26.0
T status 0.627
T2 2 (5.1) 6 (2.3) 10 (1.7)
T3 1 (2.6) 5 (1.9) 9 (1.5)
T4 36 (92.3) 250 (95.8) 562 (96.8)
LN status
N0 2 (5.1) 1 (0.4) 13 (2.2) 0.118
N1 8 (20.5) 41 (15.7) 86 (14.8)
N2 11 (28.2) 52 (19.9) 136 (23.4)
N3 18 (46.2) 167 (64.0) 346 (59.6)
Positive margins (R1 resection) 8 (20.5) 48 (18.4) 84 (14.5) 0.255
Lymphatic invasiona 0.442
No 8 (21.1) 35 (13.5) 88 (15.4)
Yes 30 (78.9) 225 (86.5) 484 (84.6)
Vascular invasiona 0.767
No 30 (78.9) 204 (79.1) 439 (76.9)
Yes 8 (21.1) 54 (20.9) 132 (23.1)
Perineural invasiona 0.003
No 17 (45.9) 57 (22.2) 175 (30.8)
Yes 20 (54.1) 200 (77.8) 394 (69.2)
Complicationsb 8 (20.5) 44 (16.9) 101 (17.4) 0.854
Surgery-related 8 (20.5) 35 (13.4) 71 (12.2) 0.316
Leakage 4 (10.3) 19 (7.3) 34 (5.9)
Intra-abdominal abscess 4 (10.3) 12 (4.6) 28 (4.8)
Wound infection 1 (2.6) 4 (1.5) 15 (2.6)
Bleeding 1 (2.6) 8 (3.1) 9 (1.5)
Delayed gastric emptying 0 1 (0.4) 4 (0.7)
Others 0 3 (1.1) 3 (0.5)
Surgery unrelated 1 (2.6) 16 (6.1) 48 (8.3) 0.275
Pneumonia 0 2 (0.8) 12 (2.1)
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were performed with SPSS software for Windows, ver-
sion 13 (SPSS, Inc., Chicago, IL, USA).
Results
Demographics and clinicopathological data
Table 1 shows the demographics and clinicopathological
features of patients with stage I–III undifferentiated GC
who underwent potentially curative gastrectomy strati-
fied according to histology type. No difference was noted
in terms of the extent of lymphadenectomy, number
of lymph nodes retrieved, resection margins, surgery-
related complications, and hospital mortality among
the three groups. Older patients (P < 0.0001), larger
tumor size (P < 0.0001), higher incidences of stage III
tumors (P < 0.001), higher total complication rates (P =
0.016), and higher percentages of patients receiving ad-
juvant chemotherapy (P = 0.047) were observed in the
group of patients with MC histology than in those with
the SRCC or PDC subtypes. Compared with MC and
PDC, SRCC had female predominance (P < 0.001); higher
incidences of T4 tumors (P < 0.0001); and greater
lymphatic (P < 0.0001), vascular (P = 0.005), or perineu-
ral (P = 0.001) invasion. More total gastrectomy proce-
dures (P = 0.006), cases with N3 status (P < 0.0001), and
surgery-unrelated complications (P = 0.031) were noted
in the PDC subtype than in SRCC and MC. In stage III
undifferentiated GC patients, MC had older patients (P =
0.019), larger tumor size (P = 0.006), and more perineural
(P = 0.003) invasion than SCC and PDC (Table 2).
Analysis of prognostic factors
Univariate analysis indicated that the type of gastrec-
tomy; ratio of metastatic to examined lymph nodes;
nodal status; histology type; resection margins; presence
of lymphatic, vascular, and perineural invasion; and
patients receiving adjuvant chemotherapy were signifi-
cant prognostic factors for stage III undifferentiated
GC patients (Table 3). Multivariate analysis showed
that the following factors significantly affected survival
in stage III undifferentiated GC patients: type of gastrectomy
(total vs. subtotal; hazard ratio (HR) = 1.130; P= 0.001),
tumor size (>5 cm vs. ≤ cm; HR = 1.251; P = 0.013), ra-
tio of metastatic to examined lymph nodes (>0.34 cm
vs. ≤0.34 cm; HR = 1.892; P < 0.0001), positive resection
margins (HR = 1.238; P < 0.001), histology type (PDC vs.
MC; HR = 1.594; P = 0.04), the presence of perineural
invasion (HR = 1.335; P = 0.004), and no administration
of chemotherapy (HR = 1.381; P = 0.002) (Table 4).
Cumulative survival rates
The 5-year overall survival (OS) rates of stage I–III un-
differentiated GC patients undergoing potentially cura-
tive resection were 58.8, 59.2, and 45.1 % in SRCC, MC,
and PDC, respectively (Fig. 1; P < 0.0001). Similar OS
rates were found for stage I (Fig. 2a; P = 0.399) and stage
II (Fig. 2b; P < 0.274) patients in the three groups. Com-
pared to stage III SRCC and PDC patients, MC patients
had markedly favorable OS rates (Fig. 2c; P = 0.038).
Discussion
In accordance with previous reports [6, 10], MC of the
stomach is a rare histologic type of GC, comprising
4.4 % of the cases of undifferentiated stage I–III GC in
our study. In potentially curative resected GC (stages I–
III), MC patients were older than SRCC or PDC patients
and the tumors in MC patients were larger than those in
SRCC or PDC patients. Patients with MC were more
often diagnosed as stage III compared with the other un-
differentiated subtypes. In stage III GC, the age and size
of MC were significantly older and larger than SRCC or
PDC, respectively; lower proportions of perineural inva-
sion were identified in MC, and female predominance
was noted in SRCC in comparison with the other two
subtypes. The cumulative OS rates of stage I–III GC
patients with MC were significantly longer compared to
those with PDC, but not SRCC. Stage III GC patients
with MC had a better prognosis than those with SRCC
or PDC; the difference in survival was not evident in
stage I or II patients.
Table 2 Clinicopathological characteristics of stage III undifferentiated gastric adenocarcinoma in terms of histology type (Continued)
Cardiovascular event 0 5 (1.9) 6 (1.0)
Sepsis 0 2 (0.8) 7 (1.2)
Paralytic ileus 0 1 (0.4) 4 (0.7)
Atelectasis 0 0 5 (0.9)
Others 1 (2.6) 18 (6.9) 38 (6.5)
Hospital mortality 2 (5.1) 13 (5.0) 32 (5.5) 0.950
Chemotherapy 30 (76.9) 205 (78.5) 423 (72.8) 0.197
Figures are numbers with percentages in parentheses, unless otherwise stated
LN lymph node, MC mucinous carcinoma, SD standard deviation, PDC poorly differentiated carcinoma, SRCC signet ring cell carcinoma
aSome data were missing
bNumber of patients with event
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Table 3 Univariate analysis of prognostic factors for stage III undifferentiated gastric adenocarcinoma
Factors Median survival (months) 95 % CI for median 3-year survival (%) 5-year survival (%) P value
Age (years) 0.200
≤65 (n = 449) 23.8 20.4–27.3 39.2 29.2
>65 (n = 385) 21.8 19.0–24.6 33.5 24.1
Sex 0.374
Male (n = 474) 21.8 19.1–24.6 34.7 25.8
Female (n = 360) 25.2 21.3–29.2 38.3 28.6
Tumor size (cm) 0.223
≤5 (n = 410) 28.4 23.9–33.0 43.1 32.9
>5 (n = 420) 19.0 16.6–21.4 29.2 21.6
Type of gastrectomy <0.0001
Total (n = 308) 17.8 15.0–20.7 29.6 20.6
Subtotal (n = 526) 26.6 23.1–30.1 40.1 30.7
Extent of LN dissection 0.834
<D2 (n = 246) 24.3 19.6–28.9 36.2 27.3
≥D2 (n = 588) 22.2 19.3–25.2 36.2 26.9
T status 0.817
T1/T2 (n = 17) 17.6 5.6–9.6 41.2 32.9
T3/T4 (n = 817) 23.0 20.5–25.6 36.2 26.9
LN ratio <0.0001
≤0.34 (n = 416) 38.7 30.8–46.7 52.4 41.9
>0.34 (n = 418) 15.8 13.5–18.1 20.1 12.0
N status <0.0001
N0 (n = 15) NA 57.8 57.8
N1 (n = 129) 65.3 29.5–101.1 58.9 50.3
N2 (n = 188) 28.6 20.1–37.1 44.3 33.8
N3 (n = 52) 18.8 16.7–0.9 26.5 17.3
Histology type 0.038
MC (n = 37) 47.8 0.0–103.0 51.1 48.1
SRCC (n = 248) 20.8 16.5–25.0 36.9 26.0
PDC (n = 549) 22.3 19.5–25.1 34.9 26.1
Resection margins <0.0001
R0 (n = 709) 25.4 22.4–28.3 39.8 30.1
R1 (n = 125) 15.8 12.7–18.9 15.3 8.6
Lymphatic invasion 0.006
No (n = 125) 33.1 23.4–42.8 45.6 36.0
Yes (n = 698) 21.5 19.5–23.6 34.1 25.0
Vascular invasion 0.024
No (n = 635) 24.3 21.7–26.9 37.2 28.1
Yes (n = 185) 18.5 14.7–22.2 31.7 23.2
Perineural invasion <0.0001
No (n = 234) 31.4 19.1–43.8 46.9 40.4
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Although studies have reported the distinct clinicopath-
ological features of MC compared with non-MC, the re-
sults remain inconsistent. Kawamura et al. indicated that
the patients with MC were younger than the non-MC pa-
tients [11]. Yin et al. suggested that age had no relation-
ship with MC and non-MC and MC was associated
with a larger tumor size than non-MC [6]. Other stud-
ies found that there was no difference in the tumor
size between patients with MC and non-MC [7, 12].
Kunisaki et al. also noted that compared with non-
MC, MC had deeper invasion and more lymph node
metastasis [7]. In addition, more advanced stages were
identified in MC at the time of diagnosis compared
with non-MC [6, 7, 10, 11, 13]. In this study, we only
included stage I–III resected undifferentiated GC and
compared the clinicopathological characteristics of
MC with SRCC or PDCC. Significant differences were
noted in age; sex; size; depth of tumor invasion; nodal
involvement; disease stage; and presence of lymphatic
invasion, vascular invasion, and perineural invasion
among patients with MC, SRCC, and PDC. In the sub-
group analysis of stage III disease, our results showed
that older patients, larger tumor size, and higher per-
centages of perineural invasion were found in those
with MC histology compared with SRCC or PDC sub-
types; SRCC and PDC had female and male predomin-
ance, respectively.
The prognosis of patients with undifferentiated GC
compared with other histology is still controversial. Our
previous studies have shown that early GC patients with
SRCC had more favorable survival than those with non-
SRCC; however, advanced SRCC resulted in significantly
worse survival than non-SRCC [14]. Interestingly, Kwon
et al. found that survival in early GC patients exhibited
no difference between histological types; advanced GC
patients with SRCC had a worse prognosis than those
with other histological types [15]. Furthermore, Shim
et al. reported that SRCC is not an independent pre-
dictor of poor prognosis after curative resection for GC
[16]. Park et al. indicated that histological type was not
statistically associated with survival in stage I, II, or III pa-
tients in stage-stratified analysis [5]. Similarly, the prognosis
Table 3 Univariate analysis of prognostic factors for stage III undifferentiated gastric adenocarcinoma (Continued)
Yes (n = 582) 20.8 18.7–22.9 31.2 21.0
Chemotherapy <0.001
No (n = 179) 16.0 11.3–20.6 29.1 20.3
Yes (n = 655) 24.5 22.0–27.0 38.1 28.7
CI confidence interval, LN ratios, ratios of metastatic to examined lymph nodes, MC mucinous carcinoma, PDC poorly differentiated carcinoma, SRCC signet ring
cell carcinoma
Table 4 Multivariate analysis of prognostic factors for stage III
undifferentiated gastric adenocarcinoma
Factors Hazard ratio (HR) 95 % CI for HR P value
Lower Upper
Type of gastrectomy
Total/subtotal 1.345 1.130 1.602 0.001
Tumor size (cm)
>5/≤5 1.251 1.049 1.492 0.013
LN ratio
>0.34/≤0.34 2.262 1.892 2.704 <0.0001
Resection margins
R1/R0 1.538 1.238 1.911 <0.001
Histology type
PDC/MC 1.594 1.012 2.510 0.044
SRCC/MC 1.518 0.949 2.429 0.081
Lymphatic invasion
Yes/no 1.045 0.813 1.343 0.732
Vascular invasion
Yes/no 0.980 0.800 1.201 0.845
Perineural invasion
Yes/no 1.335 1.095 1.627 0.004
Chemotherapy
No/yes 1.381 1.125 1.694 0.002
CI confidence interval, LN ratios, ratios of metastatic to examined lymph
nodes, MC mucinous carcinoma, PDC poorly differentiated carcinoma, SRCC
signet ring cell carcinoma
Fig. 1 Cumulative overall survival (OS) rates in stage I–III gastric
cancer according to histology type
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of MC did not differ from non-MC for each stage [6]. In
contrast, Fan et al. reported that stage I and II MC patients
had a worse 5-year OS than those with SRCC (P = 0.012); a
difference in 5-year OS was not evident between stage III
SRCC and MC groups [17]. In the present study, we ex-
amined the outcomes of undifferentiated GC patients
undergoing curative intent surgery. Our results, based
on stage-stratified analysis, indicated that stage III GC
patients with MC had a better prognosis than those with
PDC or SRCC (Fig. 2c; P = 0.038); the difference in OS
was not evident in stage I or II patients (Fig. 2a, b). Im-
portantly, MC is an independent prognostic factor in
multivariate analysis in stage III disease (PDC vs. MC;
HR = 1.594; P = 0.044; Table 4), which is different from
previous reports [9].
Although stage III patients with MC had an older age
and larger tumor size than SRCC or PDC patients, less
perineural invasion was identified in MC, which might in
part explain the favorable outcome of MC over other
undifferentiated subtypes in the current study. In this re-
gard, Deng et al., using meta-analysis methodology, indi-
cated that perineural invasion is an independent poor
prognostic factor in radically resected GC [18]. In line
with their findings, our results also showed that perineural
invasion is an independent predictor for worse survival in
stage III undifferentiated GC in multivariate analysis.
Our results showed that MC had higher percentages
of stage III disease compared with SRCC or PDC. In this
regard, previous studies suggested that MC is believed to
arise initially as a typical adenocarcinoma that becomes
mucinous as the tumor progresses [12]. Furthermore,
the intra-luminal secretion of mucin decreases and the
deposit of mucin increases, resulting in intra-luminal ac-
cumulation when the tumor invades the gastric wall [19].
Other researchers have noted that MC over-expressed
mucin 2 and oligomeric mucus/gel-forming proteins com-
pared with non-MC [10]. In addition, Choi et al. showed
that MC presented statistically lower levels of β-catenin
Fig. 2 Cumulative overall survival (OS) rates in stage I (a), II (b), and III (c) gastric cancer according to histology type
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and a more advanced stage than non-MC [13]. Nonethe-
less, more studies are needed to clarify the biological
behavior and histogenesis of MC.
Conclusions
MC is a rare type of GC. Our results indicated that stage
I–III GC with a mucinous subtype presented with different
clinicopathological features (older age and larger tumor
size) and a different prognosis than SRCC and PDC sub-
types. Patients with MC are more frequently diagnosed
with stage III disease compared with other undifferentiated
subtypes. There was no difference in survival for stages I or
II among MC, SRCC, and PDC. Stage III gastric MC had
significantly better survival than SRCC or PDC.
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